Skip to main content
. Author manuscript; available in PMC: 2018 Jan 2.
Published in final edited form as: ACS Biomater Sci Eng. 2017 Sep 28;3(12):3273–3282. doi: 10.1021/acsbiomaterials.7b00600

Figure 6.

Figure 6

Relative mRNA expression of CCR2 in 22Rv1 prostate cancer cells upon treatment with PBS, MCP-1 PAMs, MCP-1 peptides, scrambled PAMs, or scrambled peptides at a noncytotoxic concentration of 5 μM. Data are expressed as mean ± SEM (n = 3; *p < 0.05, ** p < 0.01, ***p < 0.001 compared to PBS-treated group).